SERUM ELAFIN AS A MARKER OF SEVERITY IN SKIN PSORIASIS AND PSORIATIC ARTHRITIS | ||
| ALEXMED ePosters | ||
| Article 1, Volume 6, Issue 3, July 2024, Pages 50-51 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2024.313626.1926 | ||
| Authors | ||
| Tarek Hussein Abd El-Aal1; Marwa Elsaeed Eldeeb1; Yousra Hisham Abdel-Fattah2; Nourane Tawfik3; Kholod Ibrahim Elsanour* 1 | ||
| 1Department of Dermatology, Venereology, and Andrology, Faculty of Medicine, Alexandria University, Egypt. | ||
| 2Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of medicine, Alexandria university, Egypt. | ||
| 3Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Egypt. | ||
| Abstract | ||
| Psoriasis is believed to have multifactorial pathogenesis in which genetic, environmental, and immunological factors contribute to the disease. Elafin, an anti-inflammatory serine protease inhibitor, is one of the natural AMPs and is generated by immune cells, keratinocytes, and epithelial cells.) Elafin is hardly present in healthy skin. However, it is highly expressed in psoriatic patients' urine, sputum, and epidermis.( Psoriatic Arthritis (PsA) is an inflammatory musculoskeletal illness that can be associated with all types of psoriasis of varying severity. AIM: The present study assessed serum Elafin in psoriatic patients, and its relation to the severity of skin disease as well as its association with Psoriatic Arthritis (PsA). PATIENTS AND METHODS: This cross-sectional study included forty psoriatic patients and forty healthy individuals. Serum Elafin was measured in all subjects using ELISA (Enzyme-Linked Immunosorbent Assay), skin disease was assessed using the PASI score, and psoriatic arthritis was assessed using the DASPA score. | ||
| Keywords | ||
| Elafin; psoriasis; psoriatic arthritis | ||
|
Supplementary Files
|
||
|
Statistics Article View: 123 |
||
